Moreover, we investigated the presence of CD45+ CTCs in CRC, breast cancer (BC) and NSCLC patients by detecting the epithelial-mesenchymal markers EpCAM, Vimentin, or abnormal expression of ERBB2, or CK (Fig. 1c). Here, PTPRC is linked to breast cancer.